Company intelligence
eptivA Therapeutics Ltd.
A clinical stage biotech company utilising novel Personalized Analgesics® research to create precision pain medicines
Biotechnology Research
Oxford, GB
2 employees
6 public signals
About eptivA Therapeutics Ltd.
Eptiva Therapeutics is a clinical stage Biotech company transforming the way pain is treated with PERSONALIZED ANALGESICS®. We have invented novel in silico research methods to create the first precision medicine approach to pain.
Verified activity
Signals from eptivA Therapeutics Ltd.
6 published signals
Research & Knowledge
eptivA Therapeutics Ltd. published a new Nature Communications paper by Negm and colleagues examining the spinal circuitry associated with mechanical allodynia after nerve injury using two-photon calcium imaging in an ex vivo mouse somatosensory preparation.
Reported by Mark J. Field
Research & Knowledge
eptivA Therapeutics Ltd. published a new Science paper in 2026 showing that a non-hallucinogenic 5-HT2A agonist produces similar protection in preclinical models.
Reported by Mark J. Field
Capital & Finance
eptivA Therapeutics Ltd. secured a $150m financing behind the development of neridronate in CRPS.
Reported by Mark J. Field
Research & Knowledge
eptivA Therapeutics Ltd. published a study in PAIN showing that GLP-1 receptor agonists reduce painful diabetic peripheral neuropathy in 10.1% of people with type 2 diabetes compared to standard treatment in 35.1%
Reported by Mark J. Field
Research & Knowledge
eptivA Therapeutics Ltd. published a critical appraisal by Ziegler and colleagues of a randomised trial on GLP-1 receptor agonists for diabetic peripheral neuropathy
Reported by Mark J. Field
Research & Knowledge
eptivA Therapeutics Ltd. published a study showing that GLP-1 receptor agonists increase the risk of developing diabetic lumbosacral radiculoplexus neuropathy
Reported by Mark J. Field